Sulfuric Acid — predicted protein targets

Known targets — ChEMBL curated mechanism

ADRA1A ADRA1B ADRA1D ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 ADRB3 CALCRL CHRM1 CHRM2 CHRM3 F2R MAOA MAOB MAP2K1 MAP2K2 NTRK1 NTRK2 NTRK3 OPRD1 OPRK1 OPRM1 P2RY12 PKLR SCN10A SCN11A SCN1A SCN2A SCN3A SCN4A SCN5A SCN7A SCN8A SCN9A SLC18A2 SLC6A2 SLC6A3 TLR7 TLR9 TUBA1A TUBA1B TUBA1C TUBA3C TUBA3E TUBA4A TUBB TUBB1 TUBB2A TUBB2B TUBB3 TUBB4A TUBB4B TUBB6 TUBB8 dacA dacB dacC folA ftsI mrcA mrcB mrdA pol rplA rplB rplC rplD rplE rplF rplI rplJ rplK rplL rplM rplN rplO rplP rplQ rplR rplS rplT rplU rplV rplW rplX rplY rpmA rpmB rpmB1 rpmB2 rpmC rpmD rpmE rpmE2 rpmF rpmG rpmG1 rpmG2 rpmH rpmI rpmJ rpmJ2 rpsA rpsB rpsC rpsD rpsE rpsF rpsG rpsH rpsI rpsJ rpsK rpsL rpsM rpsN rpsO rpsP rpsQ rpsR rpsR1 rpsR2 rpsS rpsT rpsU rpsZ ykgM ykgO

The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

	gene	UniProt	supporting neighbours	confidence
▸	TAAR1	Q96RJ0	1/20	0.52

▸	GPR84	Q9NQS5	1/20	0.48

▸	XIAP	P98170	1/20	0.46

▸	DAO	P14920	2/20	0.45

▸	AKR1C3	P42330	1/20	0.45

▸	HRH3	Q9Y5N1	1/20	0.44

▸	CNR1	P21554	1/20	0.43

▸	ALDH1A1	P00352	4/20	0.42

▸	HTT	P42858	1/20	0.42

▸	NPSR1	Q6W5P4	1/20	0.42

▸	IDO1	P14902	1/20	0.42

▸	CTBP2	P56545	1/20	0.41

▸	NR3C2	P08235	1/20	0.41

▸	KMT2A	Q03164	1/20	0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL2360490	0.89	TAAR1 (0.63)	TAAR1GPR84DAOHRH3CNR1
SCHEMBL3891030	0.80	TAAR1 (0.53)	TAAR1GPR84XIAPDAOAKR1C3
SCHEMBL23654200	0.77	TAAR1 (0.50)	TAAR1GPR84XIAPDAOAKR1C3
SCHEMBL3894959	0.77	ALDH1A1 (0.53)	TAAR1ALDH1A1IDO1CTBP2KMT2A
SCHEMBL11713410	0.77	TAAR1 (0.59)	TAAR1GPR84DAOHRH3IDO1
M-Xylene SCHEMBL10416113	0.76	ACHE (0.67)	ALDH1A1KMT2A
SCHEMBL29596752	0.76	TAAR1 (0.74)	TAAR1GPR84XIAPDAOHRH3
SCHEMBL8096473	0.76	TAAR1 (0.74)	TAAR1GPR84XIAPDAOHRH3
SCHEMBL5248849	0.76	TAAR1 (0.57)	TAAR1DAOHRH3IDO1
M-Xylene SCHEMBL8640080	0.74	ACHE (0.63)	ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
CN-102516115-B	As the antagonist of Opioid Receptors or the new compound of inverse agonist	SMITHKLINE BEECHAN CORP. (US)	2016-05-11	—	—	CN	disclosed
US-20140323487-A1	Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors	GLAXOSMITHKLINE LLC	2014-10-30	—	—	US	disclosed
US-8822518-B2	Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction	GLAXOSMITHKLINE LLC (US)	2014-09-02	—	—	US	disclosed
CN-103980151-A	Novel compounds as antagonists or inverse agonists at opioid receptors	SMITHKLINE BEECHAM CORP	2014-08-13	—	—	CN	disclosed
CN-101522614-B	Compounds as antagonists or inverse agonists of opioid receptors	SMITHKLINE BEECHAM CORP	2014-06-25	—	—	CN	disclosed
US-20140100255-A1	Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors	GLAXOSMITHKLINE LLC (US)	2014-04-10	—	—	US	disclosed
US-8633175-B2	Compounds as antagonists or inverse agonists at opioid receptors	GLAXOSMITHKLINE LLC (US)	2014-01-21	—	—	US	disclosed
CN-102516115-A	Novel compounds as antagonists or inverse agonists at opioid receptors	SMITHKLINE BEECHAM CORP	2012-06-27	—	—	CN	disclosed
US-20110124559-A1	NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS	SMITHKLINE BEECHAM CORPORATION (US)	2011-05-26	—	—	US	disclosed
US-20100113512-A1	METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS	IGNAR DIANE MICHELE	2010-05-06	—	—	US	disclosed
CN-101522614-A	Novel compounds as antagonists or inverse agonists of opioid receptors	SMITHKLINE BEECHAM CORP (US)	2009-09-02	—	—	CN	disclosed
EP-2054383-A2	NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS	SmithKline Beecham Corporation (US)	2009-05-06	—	—	EP	disclosed
WO-2008021849-A2	NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS	SMITHKLINE BEECHAM CORPORATION (US)	2008-02-21	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20110124559-A1	NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS	OPRL1, OPRM1, OPRK1	TAAR1 92/4885GPR84 70/4885XIAP 2094/4885
US-20100113512-A1	METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS	OPRL1, OPRD1, OPRK1	TAAR1 53/4885GPR84 95/4885XIAP 1451/4885
US-20140323487-A1	Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors	OPRL1, OPRM1, OPRK1	TAAR1 92/4885GPR84 70/4885XIAP 2094/4885
US-20140100255-A1	Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors	OPRL1, OPRM1, OPRK1	TAAR1 92/4885GPR84 70/4885XIAP 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.